The end of the Genome Project.
|
Will gene therapy give Chinese researchers an edge over their rivals in the United States?
|
Borrowing the software model to spur innovation in life sciences finds common ground with IT.
|
The technology is generating renewed interest in the VC and medical communities.
|
Scientists discover how the most deadly malaria parasite tricks the immune system.
|
Researchers employ technology used in emailing to solve a well-known problem in detecting gene activation.
|
Gene therapy company Oxford BioMedica announces a licensing deal with Pfizer.
|
Inovio Biomedical fights skeptics and a troubled history to get its electrically charged tumor treatment into doctors’ hands.
|
Combo drugs work for heart disease; the Medicis-Inamed deal is delayed; more questions about Vioxx marketing; Dharmacon to supply siRNA library.
|
New finding may push forward treatments for age-related macular degeneration, the most common cause of blindness in the elderly.
|
Advisory panel recommends FDA approval for whooping cough vaccines; genetics and insurance still don’t mix; Medtronic loses patent case; FDA gets more reports of side effects; Viasys makes a pulmonary-market move; Baxter ‘corrects’ itself; the FDA clears ANS and Boston Scientific.
|
WeSpot detects $2M; Cambridge Gateway Fund sets sights on Silicon Fen with $46.5M; two more European wireless firms get funding; Pollen pitches; and more.
|
The European biotech sector has taken a beating this year. But this sell-off has created several compelling opportunities for investors. Find out who we think are the cream of the European biotech crop.
|
Commentary: Senior writer Stephan Herrera says the recent publication of competing human genome maps has created a stir for all the wrong reasons.
|
Two biotech greats uncork DNA semiconductors.
|